Home > Insider Trading > Filing (0001209191-20-049425)

Filing Details

Accession Number:: 0001209191-20-049425
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-09-03 16:44:37
Reporting Period:: 2020-09-01

Accepted Time:: 2020-09-03 16:44:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	Biological Products, (No Disgnostic Substances) (2836)	473173478

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1682017	Rodger Novak	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139	President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2020-09-01	3,933	$14.00	651,940	No	4	M	Direct
Common Shares	Acquisiton	2020-09-01	21,067	$14.43	673,007	No	4	M	Direct
Common Shares	Disposition	2020-09-01	1,406	$91.54	671,601	No	4	S	Direct
Common Shares	Disposition	2020-09-01	19,754	$92.59	651,847	No	4	S	Direct
Common Shares	Disposition	2020-09-01	3,840	$93.19	648,007	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2020-09-01	3,933	$0.00	3,933	$14.00
Common Shares	Stock Option (Right to Buy)	Disposition	2020-09-01	21,067	$0.00	21,067	$14.43

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
111,893		2026-10-18	No	4	M	Direct
215,315		2027-06-15	No	4	M	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.93 to $91.805, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.99 to $92.965, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.005 to $93.81, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.
This option was granted on June 15, 2017 with respect to 270,000 Common Shares and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule.